Top Markets
#1 NKN NKN +185.61%
#2 Black Phoenix Black Phoenix +99.33%
#3 Liquid Mercury Liquid Mercury +33.08%
#4 Codatta Codatta +28.59%
#5 Saakuru Saakuru +25.06%
#6 Particle Network Particle Network +17.23%
#7 Bedrock Bedrock +16.99%
#8 Arcblock Arcblock +14.20%
#9 Janction Janction +13.83%
#10 TronBank TronBank +13.81%
Coin of the day
NKN NKN
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Classement en actions #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prix de l'action
$208.57
Capitalisation boursière
$368.78B
Changement (1 jour)
0.68%
Changement (1 an)
3.61%
Pays
US
Échange AbbVie Inc. (ABBV)

Catégorie

Healthcare
Ratio P/B pour AbbVie Inc. (ABBV)
Ratio P/B au March 2026 TTM : -119.61
Selon les derniers rapports financiers et le cours de l'action de AbbVie Inc., le ratio cours/valeur comptable actuel (TTM) est -119.61. À la fin de 2024, le ratio P/B était de 94.54.
Historique du ratio P/B pour AbbVie Inc. de 2009 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) -119.61 -100.00%
2025 0.00 -100.00%
2024 94.54 257.48%
2023 26.45 59.43%
2022 16.59 6.65%
2021 15.55 13.87%
2020 13.66 -185.13%
2019 -16.05 -4.60%
2018 -16.82 -155.55%
2017 30.28 38.22%
2016 21.91 -10.22%
2015 24.40 -59.27%
2014 59.92 220.74%
2013 18.68 16.62%
2012 16.02 237.93%
2011 4.74 31.60%
2010 3.60 0.00%
2009 0.00 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 33.3372 -127.87%
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 6.0657 -105.07%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 7.1931 -106.01%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 6.3334 -105.30%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 5.4725 -104.58%
US